Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.56 |
| ▸ | PNLIP | P16233 | 3/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.56 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9864391 | 1.00 | PTPN1 (0.56) | PTPN1PNLIPPTPN2TAS2R31POLB | |
| SCHEMBL13722523 | 1.00 | PTPN1 (0.56) | PTPN1PNLIPPTPN2TAS2R31POLB | |
| SCHEMBL24264493 | 1.00 | PTPN1 (0.56) | PTPN1PNLIPPTPN2TAS2R31POLB | |
| SCHEMBL25667472 | 0.92 | PTPN1 (0.54) | PTPN1PNLIPPTPN2TAS2R31POLB | |
| SCHEMBL14667947 | 0.88 | TAS2R31 (0.52) | PTPN1PNLIPPTPN2TAS2R31POLB | |
| Copalic Acid SCHEMBL34460866 | 0.88 | TAS2R31 (0.66) | PTPN1PNLIPPTPN2TAS2R31POLB | |
| Copalic Acid SCHEMBL25221800 | 0.88 | TAS2R31 (0.66) | PTPN1PNLIPPTPN2TAS2R31POLB | |
| Copalic Acid SCHEMBL29481956 | 0.88 | TAS2R31 (0.66) | PTPN1PNLIPPTPN2TAS2R31POLB | |
| SCHEMBL25666955 | 0.88 | PNLIP (0.53) | PTPN1PNLIPPTPN2TAS2R31POLB | |
| SCHEMBL25667484 | 0.88 | PNLIP (0.53) | PTPN1PNLIPPTPN2TAS2R31POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183761-A1 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | FIRMENICH SA (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183761-A1 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | FIRMENICH SA (CH) | 2023-06-15 | — | — | US | disclosed |
| WO-2021005097-A9 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | FIRMENICH SA (CH) | 2022-02-24 | — | — | WO | disclosed |
| WO-2021005097-A1 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | FIRMENICH SA (CH) | 2021-01-14 | — | — | WO | disclosed |
| US-20140249329-A1 | C-HALOGEN BOND FORMATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249329-A1 | C-HALOGEN BOND FORMATION | CBR3, FOS, CBR1 | PTPN1 4595/4885PNLIP 4272/4885PTPN2 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.